|Mr. Sebastien Plouffe||CEO & Director||N/A||N/A||1972|
|Mr. Patrick Joseph Meagher CPA, CA||CFO & Director||N/A||N/A||1986|
|Dr. Simon Beaudoin||Chief Technical Science Officer||N/A||N/A||1984|
|Dr. Moutih Rafei||VP R&D & Director||N/A||N/A||1982|
|Ms. Carrie Cesarone||Corp. Sec.||N/A||N/A||1965|
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its product pipeline focuses on the intracellular access by various types of vaccine and by protein-delivery system, such as monoclonal antibody-based therapies. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Defence Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.